2020
Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic
Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G, Brown TS, Der Nigoghossian C, Zidar DA, Haythe J, Brodie D, Beckman JA, Kirtane AJ, Stone GW, Krumholz HM, Parikh SA. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic. Journal Of The American College Of Cardiology 2020, 75: 2352-2371. PMID: 32201335, PMCID: PMC7198856, DOI: 10.1016/j.jacc.2020.03.031.Peer-Reviewed Original ResearchConceptsHealth care workersCare workersCardiovascular ConsiderationsCardiovascular careCOVID-19Severe acute respiratory syndrome coronavirus 2Pre-existing cardiovascular diseaseAcute respiratory syndrome coronavirus 2Health systemRespiratory syndrome coronavirus 2Indirect cardiovascular complicationsCardiovascular side effectsAcute myocardial injurySyndrome coronavirus 2Coronavirus disease 2019Cardiovascular complicationsVenous thromboembolismMyocardial injuryCoronavirus 2Cardiovascular diseaseCardiovascular conditionsDisease 2019Severe diseaseSide effectsRapid triage
2013
Ethical Oversight: Serving the Best Interests of Patients
Selby JV, Krumholz HM. Ethical Oversight: Serving the Best Interests of Patients. The Hastings Center Report 2013, 43: s34-s36. PMID: 23315893, DOI: 10.1002/hast.138.Peer-Reviewed Original Research
2009
Relationships with the drug industry: More regulation, greater transparency
Krumholz HM, Ross JS. Relationships with the drug industry: More regulation, greater transparency. The BMJ 2009, 338: b211. PMID: 19193612, DOI: 10.1136/bmj.b211.Commentaries, Editorials and Letters
1997
Guide to primary prevention of cardiovascular diseases. A statement for healthcare professionals from the Task Force on Risk Reduction. American Heart Association Science Advisory and Coordinating Committee.
Grundy S, Balady G, Criqui M, Fletcher G, Greenland P, Hiratzka L, Houston-Miller N, Kris-Etherton P, Krumholz H, LaRosa J, Ockene I, Pearson T, Reed J, Washington R, Smith S. Guide to primary prevention of cardiovascular diseases. A statement for healthcare professionals from the Task Force on Risk Reduction. American Heart Association Science Advisory and Coordinating Committee. Circulation 1997, 95: 2329-31. PMID: 9142014, DOI: 10.1161/01.cir.95.9.2329.Peer-Reviewed Original ResearchWhen to start cholesterol-lowering therapy in patients with coronary heart disease. A statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction.
Grundy S, Balady G, Criqui M, Fletcher G, Greenland P, Hiratzka L, Houston-Miller N, Kris-Etherton P, Krumholz H, LaRosa J, Ockene I, Pearson T, Reed J, Smith S, Washington R. When to start cholesterol-lowering therapy in patients with coronary heart disease. A statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction. Circulation 1997, 95: 1683-5. PMID: 9118557, DOI: 10.1161/01.cir.95.6.1683.Peer-Reviewed Original ResearchMeSH KeywordsAnticholesteremic AgentsCardiologyCoronary DiseaseHealth PersonnelHumansRisk FactorsSocieties, MedicalTime FactorsUnited StatesConceptsCholesterol-lowering therapyAggressive cholesterol-lowering therapyAtherosclerotic diseaseCholesterol loweringAmerican Heart Association Task ForceCholesterol-lowering trialsClinical atherosclerotic diseaseFuture coronary eventsHigh-risk patientsSubstantial clinical benefitMajority of patientsCoronary heart diseaseLDL cholesterol loweringPrimary care physiciansBenefits of therapyRisk-reducing treatmentsNonpharmaceutical approachesRecurrent CHDCoronary eventsCare physiciansClinical benefitCholesterol managementClinical managementHeart diseaseCholesterol reduction